Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial. PIVOT IO 001 (ClinicalTrials.gov identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Diab, Adi, Gogas, Helen, Sandhu, Shahneen, Long, Georgina V., Ascierto, Paolo A., Larkin, James, Sznol, Mario, Franke, Fabio, Ciuleanu, Tudor E., Pereira, Caio, Muñoz Couselo, Eva, Bronzon Damian, Fernanda, Schenker, Michael, Perfetti, Aldo, Lebbe, Celeste, Quéreux, Gaëlle, Meier, Friedegund, Curti, Brendan D., Rojas, Carlos, Arriaga, Yull, Yang, Haisu, Zhou, Ming, Ravimohan, Shruthi, Statkevich, Paul, Tagliaferri, Mary A., Khushalani, Nikhil I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602507/
https://www.ncbi.nlm.nih.gov/pubmed/37651676
http://dx.doi.org/10.1200/JCO.23.00172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602507/
https://www.ncbi.nlm.nih.gov/pubmed/37651676
http://dx.doi.org/10.1200/JCO.23.00172

Ejemplares similares